Pseudomonas
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis (NCT04596319) | Armata Pharmaceuticals, Inc. | 2020-12-22 |
| Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis (NCT02894684) | Liverpool Heart and Chest Hospital NHS Foundation Trust | 2017-01-01 |
Track Pseudomonas automatically
Every clearance here is in the API, with alerts when new ones post.